DOI QR코드

DOI QR Code

Prostate Cancer and Metabolic Syndrome: Is there a link?

  • McGrowder, Donovan A. (Department of Pathology, Faculty of Medical Sciences, The University of the West Indies) ;
  • Jackson, Lennox Anderson (Radiology West) ;
  • Crawford, Tazhmoye V. (Health Policy Department, Independent Health Policy Consultant)
  • Published : 2012.01.31

Abstract

Metabolic syndrome has become quite prevalent within our society. Over the past two decades, the prevalence of metabolic syndrome has sharply increased worldwide and it has become a major public health problem in several countries. It is associated with the global epidemic of obesity and diabetes mellitus and imposes numerous cardiovascular risks. Prostate cancer is the second most common cancer among men, surpassed only by non-melanoma skin cancer. A considerable body of evidence exists suggesting that some components of the metabolic syndrome have been associated with the risk of prostate cancer. These components include obesity, an abdominal fat distribution, and hyperinsulinemia. Androgen deprivation therapy (ADT) is the most widely used therapeutic modality in prostate cancer. It changed the body composition and lipid profile of men with prostate cancer. Androgen deficiency is associated with increased levels of total cholesterol, low-density lipoprotein (LDL)-cholesterol, increased production of proinflammatory factors, and increased thickness of the arterial wall and contributes to endothelial dysfunction. The aim of this review is to evaluate the association between metabolic syndrome and prostate cancer and to discuss the implications of androgen deficiency in men with cardiovascular risk factors. A comprehensive literature search was carried out with the use of PubMed from 1980 through 2011, and relevant articles pertinent to metabolic syndrome and prostate cancer are evaluated and discussed.

Keywords

References

  1. Ahonen MH, Tenkanen L, Teppo L, et al (2000). Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control, 11, 847-52. https://doi.org/10.1023/A:1008923802001
  2. Andersson SO, Wolk A, Bergstrom R, et al (1997). Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst, 89, 385- 9. https://doi.org/10.1093/jnci/89.5.385
  3. Araujo AB, O'Donnell AB, Brambilla DJ, et al (2004). Prevalence and incidence of androgen deficiency in middleaged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab, 89, 5920-26. https://doi.org/10.1210/jc.2003-031719
  4. Attia N, Tamborlane WV, Heptulla R, et al (1998). The metabolic syndrome and insulin-like growth factor I regulation in adolescent obesity. J Clin Endocrinol Metab, 83, 1467-71. https://doi.org/10.1210/jc.83.5.1467
  5. Baillargeon J, Pollock BH, Kristal AR, et al (2005). The association of body mass index and prostate-specific antigen in a population-based study. Cancer, 103, 1092-95. https://doi.org/10.1002/cncr.20856
  6. Baillargeon J, Rose DP (2006). Obesity, adipokines, and prostate cancer. Int J Oncol, 28, 737-45.
  7. Balkau B, Charles MA, Drivsholm T, et al (2002). European Group for the Study of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab, 28, 364-76.
  8. Bañez LL, Hamilton RJ, Partin AW, et al (2007). Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA, 298, 2275-80. https://doi.org/10.1001/jama.298.19.2275
  9. Barnard RJ, Aronson WJ, Tymchuk CN, et al (2002). Prostate cancer: another aspect of the insulin-resistance syndrome? Obes Rev, 3, 303-8. https://doi.org/10.1046/j.1467-789X.2002.00081.x
  10. Basaria S (2008). Androgen Deprivation Therapy, Insulin Resistance, and Cardiovascular Mortality: An Inconvenient Truth. J of Andrology, 29, 534-9. https://doi.org/10.2164/jandrol.108.005454
  11. Basaria S, Dobs AS (1999). Risks versus benefits of testosterone therapy in elderly men. Drugs Aging, 15, 131-42. https://doi.org/10.2165/00002512-199915020-00006
  12. Basaria S, Dobs AS (2001). Hypogonadism and androgen replacement therapy in elderly men. Am J Med, 110, 563-72. https://doi.org/10.1016/S0002-9343(01)00663-5
  13. Basaria S, Lieb J 2nd, Tang AM, et al (2002). Longterm effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf), 56, 779-86. https://doi.org/10.1046/j.1365-2265.2002.01551.x
  14. Basaria S, Muller DC, Carducci MA, et al (2006). Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen deprivation therapy. Cancer, 106, 581-88. https://doi.org/10.1002/cncr.21642
  15. Beebe Dimmer JL, Nock NL, Neslund-Dudas C, et al (2009). Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology, 74, 185-90. https://doi.org/10.1016/j.urology.2009.03.013
  16. Beebe Dimmer JL, Dunn RL, Sarma AV, et al (2007). Features of the metabolic syndrome and prostate cancer in African- American men. Cancer, 109, 875-81. https://doi.org/10.1002/cncr.22461
  17. Bianchini F, Kaaks R, Vainio H (2002). Overweight, obesity, and cancer risk. Lancet Oncol, 3, 565-74. https://doi.org/10.1016/S1470-2045(02)00849-5
  18. Bolla B, Gonzalez D, Warde P, et al (1997). Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med, 337, 295-300. https://doi.org/10.1056/NEJM199707313370502
  19. Boyle BJ, Zhao XY, Cohen P, et al (2001). Insulin-like growth factor binding protein-3 mediates 1a,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol, 165, 1319-24. https://doi.org/10.1016/S0022-5347(01)69892-6
  20. Braga Basaria M, Dobs AS, Muller DC, et al (2006b). Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol, 24, 3979-83. https://doi.org/10.1200/JCO.2006.05.9741
  21. Braga-Basaria M, Muller DC, Carducci MA, et al (2006a). Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res, 18, 494-8. https://doi.org/10.1038/sj.ijir.3901471
  22. Bratt O (2002). Hereditary prostate cancer: clinical aspects. J Urol, 168, 906-13. https://doi.org/10.1016/S0022-5347(05)64541-7
  23. Bratt O, Rohrmann S, Landis PK, et al (2004). Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology, 2, 253-8.
  24. Calle EE, Rodriguez C, Walker-Thurmond K, et al (2003). Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med, 348, 1625-38. https://doi.org/10.1056/NEJMoa021423
  25. Chodak GW, Keane T, Klotz L (2002). Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology, 60, 201-8. https://doi.org/10.1016/S0090-4295(02)01677-1
  26. Chrousos GP (1998). Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. Ann NY Acad Sci, 851, 311-35. https://doi.org/10.1111/j.1749-6632.1998.tb09006.x
  27. Chun FK, Hutterer GC, Perrotte P, et al (2007). Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. BJU Int, 100, 37-41. https://doi.org/10.1111/j.1464-410X.2007.06923.x
  28. Cohen PA, Kaufman JM, Deslypere JP, et al (1993). Attenuated luteinizing hormone (LH) pulse amplitude but normal pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab, 76, 1140-46. https://doi.org/10.1210/jc.76.5.1140
  29. Cohen P, Peehl DM, Lamson G, et al (1991). Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab, 73, 401-7. https://doi.org/10.1210/jcem-73-2-401
  30. Cohen PG (2008). Obesity in men: the hypogonadal-estrogen receptor relationship and its effect on glucose homeostasis. Med. Hypotheses, 70, 358-60. https://doi.org/10.1016/j.mehy.2007.05.020
  31. Coman I, Cri-an N, Marian A, et al (2008). Prevalence of the metabolic syndrome in patients with prostate cancer. J Gastrointestin Liver Dis, 17, 237-8.
  32. Cooperberg MR, Lubeck DP, Meng MV, et al (2004). The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol, 22, 2141-9. https://doi.org/10.1200/JCO.2004.10.062
  33. Cooperberg MR, Grossfeld GD, Lubeck DP, et al (2003). National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst, 95, 981-9. https://doi.org/10.1093/jnci/95.13.981
  34. Corder EH, Guess HA, Hulka BS, et al (1993). Vitamin D and prostate cancer: A prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev, 2, 467-72.
  35. Dandona P, Dhindsa S, Chaudhuri A, et al (2008). Hypogonadotrophic hypogonadism in type 2 diabetes. Aging Male, 11, 107-17. https://doi.org/10.1080/13685530802317934
  36. De Santana IA, Moura GS, Vieira NF (2008). Metabolic syndrome in patients with prostate cancer. Sao Paulo Med J, 126, 274-8. https://doi.org/10.1590/S1516-31802008000500006
  37. Dunn SE, Kari FW, French J, et al (1997). Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53- deficient mice. Cancer Res, 57, 4667-72.
  38. Eckel RH, Grundy SM, Zimmet PZ (2005). The metabolic syndrome. Lancet, 365, 1415-28. https://doi.org/10.1016/S0140-6736(05)66378-7
  39. Engeland A, Tretli S, Bjorge T (2003). Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men. Br J Cancer, 89, 237-42.
  40. Eri LM, Urdal P, Bechensteen AG (1995). Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol, 154, 100-4. https://doi.org/10.1016/S0022-5347(01)67239-2
  41. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (2001). Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 285, 2486-97. https://doi.org/10.1001/jama.285.19.2486
  42. Ford ES, Giles WH, Dietz WH (2002). Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA, 287, 356-9. https://doi.org/10.1001/jama.287.3.356
  43. Ford ES, Giles WH, Mokdad AH (2004). Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care, 27, 2444-9. https://doi.org/10.2337/diacare.27.10.2444
  44. Freedland SJ, Platz EA (2007). Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev, 29, 88-97. https://doi.org/10.1093/epirev/mxm006
  45. Freedland SJ, Platz EA, Presti JC Jr, et al (2006). Obesity, serum prostate specific antigen and prostate size: Implications for prostate cancer detection. J Urol, 175, 500-4. https://doi.org/10.1016/S0022-5347(05)00162-X
  46. Freedland SJ, Terris MK, Platz EA, et al (2005). Body mass index as a predictor of prostate cancer: Development versus detection on biopsy. Urology, 66, 108-13.
  47. Gann PH, Hennekens CH, Ma J, et al (1996). Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst, 88, 1118-26. https://doi.org/10.1093/jnci/88.16.1118
  48. Golden SH, Robinson KA, Saldanha I, et al (2009). Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab, 94, 1853-78. https://doi.org/10.1210/jc.2008-2291
  49. Garnick MB (1986). Leuprolide versus diethylstilbestrol for previously untreated stage D2 prostate cancer. Results of a prospectively randomized trial. Urology, 27, 21-28. https://doi.org/10.1016/S0090-4295(86)80006-1
  50. Giovannucci E, Rimm EB, Liu Y, et al (2003). Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst, 95, 1240-4. https://doi.org/10.1093/jnci/djg009
  51. Gronberg H (2003). Prostate cancer epidemiology. Lancet, 36, 859-64. https://doi.org/10.1016/S0140-6736(02)97652-X
  52. Grubb RL III, Black A, Izmirlian G, et al (2009). Serum prostatespecific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev, 18, 748-51. https://doi.org/10.1158/1055-9965.EPI-08-0938
  53. Grundy SM, Brewer HB Jr, Cleeman JI, et al (2004). Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol, 24, e13-e18. https://doi.org/10.1161/01.ATV.0000111245.75752.C6
  54. Guay AT (2009). The emerging link between hypogonadism and metabolic syndrome. J Androl, 30, 370-6. https://doi.org/10.2164/jandrol.108.006015
  55. Gugliotta A, Ferreira U, Reis LO, et al (2008). Satisfaction analysis in men presenting with localized prostate cancer treated with radical prostatectomy or radiotherapy: psychological and social aspects. Actas Urol Esp, 32, 411-6. https://doi.org/10.1016/S0210-4806(08)73855-5
  56. Haffner S, Taegtmeyer H (2003). Epidemic Obesity and the Metabolic Syndrome. Circulation, 108, 1541-5 https://doi.org/10.1161/01.CIR.0000088845.17586.EC
  57. Haffner SM, Mykkanen L, Valdez RA, et al (1993). Relationship of sex hormones to lipids and lipoproteins in non-diabetic men. J Clin Endocrinol Metab, 77, 1610-5. https://doi.org/10.1210/jc.77.6.1610
  58. Hakimian P, Blute M, Kashanian J, et al (2008). Metabolic and cardiovascular effects of androgen deprivation therapy. BJU Int, 102, 1509-14. https://doi.org/10.1111/j.1464-410X.2008.07933.x
  59. Hammarsten J, Hogstedt B (2001). Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol, 39, 151-8. https://doi.org/10.1159/000052430
  60. Hammarsten J, Hogstedt B (2004). Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Pressure, 13, 47-55. https://doi.org/10.1080/08037050310025735
  61. Hammarsten J, Hogstedt B (2005). Hyperinsulinaemia: A prospective risk factor for lethal clinical prostate cancer. Eur J Cancer, 41, 2887-95. https://doi.org/10.1016/j.ejca.2005.09.003
  62. Hammarsten J, Hogstedt B, Holthuis N, et al (1998). Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis, 1, 157-62. https://doi.org/10.1038/sj.pcan.4500221
  63. Han JH, Chang IH, Ahn SH, et al (2008). Association between serum prostate- specific antigen level, liver function tests and lipid profile in healthy men. BJU Int, 102, 1097-101. https://doi.org/10.1111/j.1464-410X.2008.07774.x
  64. Hanchette CL, Schwartz GG (1992). Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer, 70, 2861-9. https://doi.org/10.1002/1097-0142(19921215)70:12<2861::AID-CNCR2820701224>3.0.CO;2-G
  65. Hernandez J, Thompson IM (2004). Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer, 101, 894-904. https://doi.org/10.1002/cncr.20480
  66. Hsing AW, Chokkalingam AP (2006). Prostate cancer epidemiology. Front Biosci, 11, 1388-413. https://doi.org/10.2741/1891
  67. Hsing AW, Devesa SS (2001). Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev, 23, 3-13. https://doi.org/10.1093/oxfordjournals.epirev.a000792
  68. Hsing AW, Devesa SS, Jin F, et al (1998). Rising incidence of prostate cancer in Shanghai, China. Cancer Epidemiol Biomarkers Prev, 7, 83-4.
  69. Hsing AW, Gao YT, Chua S Jr, et al (2003). Insulin resistance and prostate cancer risk. J Natl Cancer Inst, 95, 67-71. https://doi.org/10.1093/jnci/95.1.67
  70. Hsing AW, Sakoda LC, Chua S Jr (2007). Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr, 86, 843-57. https://doi.org/10.1093/ajcn/86.3.843S
  71. Hsing AW, Tsao L, Devesa SS (2000). International trends and patterns of prostate cancer incidence and mortality. Int J Cancer, 85, 60-7. https://doi.org/10.1002/(SICI)1097-0215(20000101)85:1<60::AID-IJC11>3.0.CO;2-B
  72. Huang PL (2009). A comprehensive definition for metabolic syndrome. Dis Model Mech, 2, 231-7. https://doi.org/10.1242/dmm.001180
  73. International Diabetes Federation (2005). The IDF consensus world-wide definition of the metabolic Syndrome Available from http://www.idf.org/webdata/docs/Metac_syndrome_ def.pdf.
  74. Isomaa B, Almgren P, Tuomi T, et al (2001). Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care, 24, 683-9. https://doi.org/10.2337/diacare.24.4.683
  75. Isom Batz G, Bianco FJ Jr, Kattan MW, et al (2005). Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol, 173, 1935-7. https://doi.org/10.1097/01.ju.0000158040.33531.e7
  76. Iwamura M, Sluss PM, Casamento JB, et al (1993). Insulinlike growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate, 22, 243-52. https://doi.org/10.1002/pros.2990220307
  77. Jayachandran J, Banez LL, Aronson WJ, et al (2009). Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer, 115, 5263-71. https://doi.org/10.1002/cncr.24571
  78. Jayachandran J, Hogstedt B (2005). Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer, 41, 2887-95. https://doi.org/10.1016/j.ejca.2005.09.003
  79. Jemal A, Siegel R, Ward E, et al (2006). Cancer statistics. CA Cancer J Clin, 56, 106-30. https://doi.org/10.3322/canjclin.56.2.106
  80. Jeong IG, Hwang SS, Kim HK, et al (2010). The Association of Metabolic Syndrome and Its Components with Serum Prostate-Specific Antigen Levels in a Korean-Screened Population. Cancer Epidemiol Biomarkers Prev, 19, 371-80. https://doi.org/10.1158/1055-9965.EPI-09-0760
  81. Jones JI, Clemmons DR (1995). Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev, 16, 3-34.
  82. Kahn SE, Prigeon RL, Schwartz RS, et al (2001). Obesity, body fat distribution, insulin sensitivity and islet beta-cell function as explanations for metabolic diversity. J Nutr, 131, 354-60. https://doi.org/10.1093/jn/131.2.354S
  83. Kapoor D, Malkin CJ, Channer KS, et al (2005). Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf), 63, 239-50. https://doi.org/10.1111/j.1365-2265.2005.02299.x
  84. Keating NL, O'Malley AJ, Smith MR (2006). Diabetes and cardiovascular disease during androgen deprivation for prostate cancer. J Clin Onco, 124, 4448-56.
  85. Kim YJ, Cho YJ, Oh JE, et al (2008). The association between metabolic syndrome and prostate-specific antigen levels. Int J Urol, 15, 905-9. https://doi.org/10.1111/j.1442-2042.2008.02137.x
  86. Kim YJ, Han BK, Hong SK, et al (2007). Body mass index influences prostate-specific antigen in men younger than 60 years of age. Int J Uro, 14, 1009-12. https://doi.org/10.1111/j.1442-2042.2007.01879.x
  87. Kristal AR, Chi C, Tangen CM, et al (2006). Associations of demographic and lifestyle characteristics with prostatespecific antigen (PSA) concentration and rate of PSA increase. Cancer, 106, 320-8. https://doi.org/10.1002/cncr.21603
  88. Laaksonen DE, Lakka HM, Niskanen LK, et al (2002). Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol, 156, 1070-7. https://doi.org/10.1093/aje/kwf145
  89. Laaksonen DE, Niskanen L, Punnonen K, et al (2004). Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care, 27, 1036-41. https://doi.org/10.2337/diacare.27.5.1036
  90. Lakka HM, Laaksonen DE, Lakka TA, et al (2002). The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA, 288, 2709-16. https://doi.org/10.1001/jama.288.21.2709
  91. Laukkanen JA, Laaksonen DE, Niskanen L, et al (2004). Metabolic syndrome and the risk of prostate cancer in Finnish men: a population - based study. Cancer Epidemiol Biomarkers Prev, 13, 1646-50.
  92. Li H, Stampfer MJ, Hollis BW, et al (2007). A Prospective Study of Plasma Vitamin D Metabolites, Vitamin D Receptor Polymorphisms, and Prostate Cancer. PLoS Medicine, 4, e103. https://doi.org/10.1371/journal.pmed.0040103
  93. Loblaw DA, Virgo KS, Nam R, et al (2007). Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol, 25, 1596-605. https://doi.org/10.1200/JCO.2006.10.1949
  94. Lund Haheim L, Wisloff TF, Holme I, et al (2006). Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol, 164, 769-74. https://doi.org/10.1093/aje/kwj284
  95. MacInnis RJ, English DR (2006). Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control, 17, 989-1003. https://doi.org/10.1007/s10552-006-0049-z
  96. Malik S, Wong ND, Franklin SS, et al (2004). Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation, 110, 1245-50. https://doi.org/10.1161/01.CIR.0000140677.20606.0E
  97. Malkin CJ, Pugh PJ, Jones RD, et al (2004). The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab, 89, 3313-8. https://doi.org/10.1210/jc.2003-031069
  98. Martin RM, Vatten L, Gunnell D, et al (2009). Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control, 20, 1181-92. https://doi.org/10.1007/s10552-009-9319-x
  99. Messing EM, Manola J, Sarosdy M, et al (1999). Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med, 341, 1781-8. https://doi.org/10.1056/NEJM199912093412401
  100. Mohile SG, Cooperberg MR, Elkin EP, et al (2003). Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol, 170, 1804-7. https://doi.org/10.1097/01.ju.0000091641.34674.11
  101. Morley JE, Kaiser FE, Perry HM, et al. (1997). Longitudinal changes in testosterone, luteinizing hormone, and folliclestimulating hormone in healthy older men. Metabolism, 46, 410-3. https://doi.org/10.1016/S0026-0495(97)90057-3
  102. Morote J, Ramirez C, Gomez E, et al (2009). The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness. BJU Int, 104, 486-9. https://doi.org/10.1111/j.1464-410X.2009.08378.x
  103. Moyad MA (2002). Is obesity a risk factor for prostate cancer, and does it even matter? A hypothesis and different perspective. Urology, 59, 41-50. https://doi.org/10.1016/S0090-4295(01)01175-X
  104. Muller M, Grobbee DE, den Tonkelaar I, et al (2005). Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab, 90, 2618-23. https://doi.org/10.1210/jc.2004-1158
  105. Mulligan T, Frick MF, Zuraw QZ, et al (2006). Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract, 60, 762-9. https://doi.org/10.1111/j.1742-1241.2006.00992.x
  106. National Cancer Institute Surveillance Epidemiology and End Results Program (2009). Retrieved from http://seer.cancer. gov/statfacts/html/prost.html.
  107. Nelson WG, De Marzo AM, Isaacs WB (2003). Prostate cancer. Mechanisms of disease. N Engl J Med, 349, 366-81. https://doi.org/10.1056/NEJMra021562
  108. Nishiyama T, Ishizaki F, Anraku T, et al (2005). The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab, 90, 657-60. https://doi.org/10.1210/jc.2004-1611
  109. Ogden C, Carroll M, McDowell M, et al (2007). Flegal K. Obesity Among Adults in the United States - No Change Since 2003-2004. Hyattsville, MD: National Center for Health Statistics.
  110. O'Malley RL, Taneja SS (2006). Obesity and prostate cancer. Can J Urol, 13 (Suppl 2), 11-7.
  111. Parekh N, Lin Y, Marcella S, et al (2008). Associations of lifestyle and physiologic factors with prostate-specific antigen concentrations: evidence from the National Health and Nutrition Examination Survey (2001-2004). Cancer Epidemiol Biomarkers Prev, 17, 2467-72. https://doi.org/10.1158/1055-9965.EPI-08-0059
  112. Park SK, Sakoda LC, Kang D, et al (2006). Rising prostate cancer rates in South Korea. Prostate, 66, 1285-91. https://doi.org/10.1002/pros.20419
  113. Peehl DM, Feldman D (2003). The role of vitamin D and retinoids in controlling prostate cancer progression. Endocr Relat Cancer, 10, 131-140. https://doi.org/10.1677/erc.0.0100131
  114. Phillips GB, Jing T, Heymsfield SB (2003). Relationships in men of sex hormones, insulin, adiposity, and risk factors for myocardial infarction. Metabolism, 52, 784-90. https://doi.org/10.1016/S0026-0495(03)00072-6
  115. Pischon T, Boeing H, Weikert S, et al (2008). Body size and risk of prostate cancer in the european prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev, 17, 3252-61. https://doi.org/10.1158/1055-9965.EPI-08-0609
  116. Platz EA, Leitzmann MF, Rifai N, et al (2005). Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev, 14, 1262-9. https://doi.org/10.1158/1055-9965.EPI-04-0371
  117. Pound CR, Partin AW, Eisenberger MA, et al (1999). Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281, 1591- 7. https://doi.org/10.1001/jama.281.17.1591
  118. Powell IJ (2007). Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol, 177, 444-9. https://doi.org/10.1016/j.juro.2006.09.024
  119. Reaven GM (1988). Banting lecture 1988. Role of insulin resistance in human disease. Diabetes, 37, 1595-607. https://doi.org/10.2337/diabetes.37.12.1595
  120. Reis LO, Sasse AD, Matheus WE, et al (2009). Prostate cancer: evidence based clinical practice. Actas Urol Esp, 33, 344-50. https://doi.org/10.1016/S0210-4806(09)74158-0
  121. Rodriguez C, Patel AV, Calle EE et al (2001). Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev, 10, 345-53.
  122. Rosmond R, Dallman MF, Bjorntorp P (1998). Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab, 83, 1853-9. https://doi.org/10.1210/jc.83.6.1853
  123. Rundle A, Neugut AI (2008). Obesity and screening PSA levels among men undergoing an annual physical exam. Prostate, 68, 373-80. https://doi.org/10.1002/pros.20704
  124. Rundle A, Richards C, Neugut AI (2009). Body composition, abdominal fat distribution, and prostate-specific antigen test results. Cancer Epidemiol Biomarkers Prev, 18, 331-6. https://doi.org/10.1158/1055-9965.EPI-08-0247
  125. Sattar N, Gaw A, Scherbakova O, et al (2003). Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation, 108, 414-19. https://doi.org/10.1161/01.CIR.0000080897.52664.94
  126. Schröder LM, Schwartz, Woloshin S (2005). Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst, 97, 1132-7. https://doi.org/10.1093/jnci/dji205
  127. Schwartz GG (2005). Vitamin D and the epidemiology of prostate cancer. Semin Dial, 18, 276-89. https://doi.org/10.1111/j.1525-139X.2005.18403.x
  128. Schwartz GG, Hulka BS (1990). Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res, 10, 1307-11.
  129. Severson RK, Grove JS, Nomura AM, et al (1988). Body mass and prostatic cancer: a prospective study. BMJ, 297, 713-5. https://doi.org/10.1136/bmj.297.6650.713
  130. Sharifi N, Gulley JL, Dahut WL (2005). Androgen deprivation therapy for prostate cancer. JAMA, 294, 238-44. https://doi.org/10.1001/jama.294.2.238
  131. Shulman AI, Mangelsdorf DJ (2005). Retinoid x receptor heterodimers in the metabolic syndrome. N Engl J Med, 353, 604-15. https://doi.org/10.1056/NEJMra043590
  132. Smith JC, Bennett S, Evans LM, et al (2001). The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab, 86, 4261-7. https://doi.org/10.1210/jc.86.9.4261
  133. Smith M, Lee H, Nathan D (2006). Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab, 91, 1305-8. https://doi.org/10.1210/jc.2005-2507
  134. Smith MR (2007). Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes, 14, 247-54. https://doi.org/10.1097/MED.0b013e32814db88c
  135. Smith MR, Finkelstein JS, McGovern FJ, et al (2002). Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab, 87, 599-603. https://doi.org/10.1210/jc.87.2.599
  136. Sprenger CC, Peterson A, Lance R, et al (2001). Regulation of proliferation of prostate epithelial cells by 1,25-dihydroxyvitamin D3 is accompanied by an increase in insulin-like growth factor binding protein-3. J Endocrinol, 170, 609-18. https://doi.org/10.1677/joe.0.1700609
  137. Stellato RK, Feldman HA, Hamdy O, et al (2000). Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care, 23, 490-4. https://doi.org/10.2337/diacare.23.4.490
  138. Stewart LV, Weigel NL (2004). Vitamin D and prostate cancer. Exp Biol Med (Maywood), 229, 277-84. https://doi.org/10.1177/153537020422900401
  139. Svartberg J, von Muhlen D, Schirmer H, et al (2004). Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromso Study. Eur J Endocrinol, 150, 65-71. https://doi.org/10.1530/eje.0.1500065
  140. Tande AJ, Platz EA, Folsom AR (2006). The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol, 164, 1094-102. https://doi.org/10.1093/aje/kwj320
  141. Teloken C, Da Ros CT, Caraver F, et al (2005). Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol, 174, 2178-80. https://doi.org/10.1097/01.ju.0000181818.51977.29
  142. The Endocrine Society (2001). Summary from the 2nd Annual Andropause Consensus Meeting. The Endocrine Society, Chevy Chase, MD: The Endocrine Society Continuing Education Medical Services.
  143. Trevisan M, Liu J, Bahsas FB, et al (1998). Risk Factor and Life Expectancy Research Group. Syndrome X and mortality: a population based study. Am J Epidemiol, 148, 958-66. https://doi.org/10.1093/oxfordjournals.aje.a009572
  144. Tuohimaa P, Tenkanen L, Ahonen M, et al (2004). Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int J Cancer, 108, 104-8. https://doi.org/10.1002/ijc.11375
  145. Tuohimaa P, Tenkanen L, Syvala H, et al (2007). Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomarkers Prev, 16, 302-7. https://doi.org/10.1158/1055-9965.EPI-06-0777
  146. Wallner LP, Morgenstern H, McGree ME, et al (2011). The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study. BJU Int, 107, 929-35. https://doi.org/10.1111/j.1464-410X.2010.09703.x
  147. Werny DM, Saraiya M, Gregg EW (2006). Prostate-specific antigen values in diabetic and non-diabetic US men, 2001- 2002. Am J Epidemiol, 164, 978-83. https://doi.org/10.1093/aje/kwj311
  148. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus.
  149. World Health Organization, 1999. Available from: http:// whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf.
  150. Wilson PW, Kannel WB, Silbershatz H, et al (1999). Clustering of metabolic factors and coronary heart disease. Arch Intern Med, 159, 1104-9. https://doi.org/10.1001/archinte.159.10.1104
  151. Yannucci J, Manola J, Garnick MB, et al (2006). The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol, 176, 520-5. https://doi.org/10.1016/j.juro.2006.03.057
  152. Zadshir A, Tareen N, Pan D, et al (2005). The prevalence of hypovitaminosis D among US adults: Data from the NHANES III. Ethn Dis, 15, 97-101.

Cited by

  1. The XRCC1 Arg280His Gene Polymorphism and Hepatocellular Carcinoma Risk: A Meta-analysis vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.2033
  2. Nutrition and prostate cancer: an overview vol.14, pp.11, 2014, https://doi.org/10.1586/14737140.2014.972946
  3. Diabetes - Increased Risk for Cancers through Chromosomal Aberrations? vol.15, pp.11, 2014, https://doi.org/10.7314/APJCP.2014.15.11.4571
  4. Association of Polymorphisms in Stress-Related TNFα and NPY Genes with the Metabolic Syndrome in Han and Hui Ethnic Groups vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5895
  5. Impact of Poster Presentations on Academic Knowledge Transfer from the Oncologist Perspective in Turkey vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7707
  6. Influence of Adipocytokines and Periprostatic Adiposity Measurement Parameters on Prostate Cancer Aggressiveness vol.15, pp.4, 2014, https://doi.org/10.7314/APJCP.2014.15.4.1879
  7. Association Analysis of Single Nucleotide Polymorphisms in miR-146a and miR-196a2 on the Prevalence of Cancer in Elderly Japanese: A Case-Control Study vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2101
  8. Diabetes Mellitus and HbA1c Levels Associated with High Grade Prostate Cancer vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2555
  9. Third-line Hormonal Therapy to Treat Prostate Cancer Relapse after Initial and Second-line Hormonal Therapy: Report of 52 Cases and Literature Review vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3645
  10. Body mass index is associated with higher Gleason score and biochemical recurrence risk following radical prostatectomy in Chinese men: a retrospective cohort study and meta-analysis vol.13, pp.1, 2015, https://doi.org/10.1186/s12957-015-0725-0
  11. Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10729
  12. Investigating the Incidence of Prostate Cancer in Iran 2005-2008 using Bayesian Spatial Ecological Regression Models vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5917
  13. Conditional PTEN-deficient Mice as a Prostate Cancer Chemoprevention Model vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1827
  14. Does metabolic syndrome or its components associate with prostate cancer when diagnosed on biopsy? vol.7, pp.2, 2015, https://doi.org/10.1177/1758834014560158
  15. Metabolic syndrome in prostate cancer: impact on risk and outcomes vol.12, pp.16, 2016, https://doi.org/10.2217/fon-2016-0061
  16. Actual lowering effect of metabolic syndrome on serum prostate-specific antigen levels is partly concealed by enlarged prostate: results from a large-scale population-based study vol.120, pp.4, 2017, https://doi.org/10.1111/bju.13621
  17. Effect of androgen deprivation therapy on arterial stiffness and serum lipid profile changes in patients with prostate cancer: a prospective study of initial 6-month follow-up vol.21, pp.2, 2016, https://doi.org/10.1007/s10147-015-0891-7
  18. The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study vol.4, pp.1, 2016, https://doi.org/10.1186/s40170-016-0161-9
  19. The Comparison and Estimation of the Prognostic Value of Lipid Profiles in Patients With Prostate Cancer Depends on Cancer Stage Advancement vol.11, pp.6, 2017, https://doi.org/10.1177/1557988317717382
  20. Meta-analysis of metabolic syndrome and prostate cancer vol.20, pp.2, 2017, https://doi.org/10.1038/pcan.2017.1
  21. Effects of barium chloride adsorbed to polyethylene glycol (PEG) microspheres on co-culture of human blood mononuclear cell and breast cancer cell lines (MCF-7) pp.1532-2513, 2017, https://doi.org/10.1080/08923973.2017.1392563
  22. Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers vol.17, pp.5, 2016, https://doi.org/10.3390/ijms17050717
  23. The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism vol.19, pp.2, 2016, https://doi.org/10.1038/pcan.2016.2
  24. Risk Analysis of Prostate Cancer Treatments in Promoting Metabolic Syndrome Development and the Influence of Increased Metabolic Syndrome on Prostate Cancer Therapeutic Outcome vol.9, pp.4, 2018, https://doi.org/10.1007/s12672-018-0335-8
  25. Physician and patient concordance of report of tobacco cessation intervention in primary care in India vol.15, pp.1, 2015, https://doi.org/10.1186/s12889-015-1803-5